This is a syndicated repost published with the permission of Money Morning - We Make Investing Profitable. To view original, click here. Opinions herein are not those of the Wall Street Examiner or Lee Adler. Reposting does not imply endorsement. The information presented is for educational or entertainment purposes and is not individual investment advice.
The Eli Lilly stock price today (Wednesday) fell as much as 4.8% after the company released new trial results on its Alzheimer’s drug solanezumab.
Eli Lilly and Co. (NYSE:LLY) officials released data from a follow-up study on two of the drug’s earlier trials. The Alzheimer’s drug fell short of its goals in the first two trials, but the new data showed encouraging signs.
The new results indicate the drug could slow the course of mental decline the longer patients take it. The drug was also said to be more effective among patients in earlier stages of the disease.
While the results were encouraging, they fell short of investors’ expectations.
The follow-up study compared new patients with those who had been taking the drug for over one and a half years. The patients who had been taking the drug longer showed stronger signs of the drug’s efficacy.
Solanezumab is designed to clear amyloid plaque buildup in the brain, which leads to cognitive decline. More than 5 million Americans suffer from Alzheimer’s currently. That number is expected to triple by 2050.
Effective Alzheimer’s drugs haven proven historically elusive for the pharmaceutical industry. According to Financial Times, more than 120 Alzheimer’s drugs have failed clinical trials since 1998.
Including today’s dip, the Eli Lilly stock price is still up 19.7% in 2015. It hit an intraday low of $81.50 shortly after the opening bell.
About Money Morning: Money Morning gives you access to a team of ten market experts with more than 250 years of combined investing experience – for free. Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors.
Disclaimer: © 2015 Money Morning and Money Map Press. All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning. 16 W. Madison St. Baltimore, MD, 21201.
The post Eli Lilly Stock Falls After Release of New Alzheimer’s Drug Data (NYSE: LLY) appeared first on Money Morning . Reposted with permission.